Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Andrew L. Pecora, MD
Published: Wednesday, Jan 03, 2018



Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.
 
SELECTED
LANGUAGE


Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x